EPO Decision To Grant European Patent For Rencofilstat Further Strengthens Hepion's Patent Portfolio
EPO Decision To Grant European Patent For Rencofilstat Further Strengthens Hepion's Patent Portfolio
– Patent Covers 38 European Countries –
– Rencofilstat's Exclusivity May Extend into 2048 –
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that the European Patent Office ("EPO") has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion's lead cyclophilin inhibitor, rencofilstat.
The newly granted European patent also significantly extends the time period of Hepion's patent exclusivity for rencofilstat. The Company's original composition-of-matter patent estate, comprising 52 patents issued in every major market throughout the world, are expected to provide exclusivity to 2036. The newly granted rights, which will encompass 38 European countries, are expected to extend the drug candidate's patent life by approximately eight years, to 2044. Additional filings are also underway to potentially extend composition-of-matter and method-of-manufacturing exclusivity until 2048. In addition to the indications covered in the original composition-of-matter patents (viral, cardiovascular, neurological, and inflammatory diseases), Hepion has also filed various method-of-use patent applications covering a variety of additional indications (fibrosis, cancer, and thrombosis).
Robert Foster, PharmD, PhD, Hepion's Chief Executive Officer, stated, "Rencofilstat is very challenging to formulate, owing to the physical-chemical properties of the molecule. Nevertheless, as awareness of its potential to address a number of significant unmet medical needs across a variety of indications continues to grow amongst researchers and drug developers in global markets, it is important this opportunity is well protected. To that end, our expanding intellectual property estate, including this new European patent, should ensure that rencofilstat has long-term market exclusivity."
– Patent Covers 38 European Countries –
— 專利覆蓋 38 個歐洲國家 —
– Rencofilstat's Exclusivity May Extend into 2048 –
— 凝積非司的排他性可能延伸到 2048 年 —
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that the European Patent Office ("EPO") has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion's lead cyclophilin inhibitor, rencofilstat.
新澤西州愛迪生，2023 年 3 月 2 日（GLOBE NEWIRE）-赫邦製藥有限公司（NASDAQ：HEPA），一家專注於人工智能（「AI」）驅動治療藥物開發的臨床階段生物製藥公司，用於治療非酒精性脂肪性肝炎（「NASH」），纖維性疾病，肝細胞癌，其他慢性疾病（「HMA」），今日宣布歐洲專利局（「EPO」）已授予歐洲專利號碼。EP 3886813，涵蓋了 HEPION 鉛環黴素抑製劑的創新配方，腎結非司。
The newly granted European patent also significantly extends the time period of Hepion's patent exclusivity for rencofilstat. The Company's original composition-of-matter patent estate, comprising 52 patents issued in every major market throughout the world, are expected to provide exclusivity to 2036. The newly granted rights, which will encompass 38 European countries, are expected to extend the drug candidate's patent life by approximately eight years, to 2044. Additional filings are also underway to potentially extend composition-of-matter and method-of-manufacturing exclusivity until 2048. In addition to the indications covered in the original composition-of-matter patents (viral, cardiovascular, neurological, and inflammatory diseases), Hepion has also filed various method-of-use patent applications covering a variety of additional indications (fibrosis, cancer, and thrombosis).
新授予的歐洲專利也大大延長了 Hepion 對瑞可非司的專利排他性的時間。該公司原始的物質成分專利資產，包括在全球各大市場發行的 52 項專利，預計將在 2036 年提供獨家權。新授予的權利將包括 38 個歐洲國家，預計將延長候選藥物的專利壽命約八年，直到 2044 年。還正在進行其他申請，以將物質成分和製造排他性的方法擴展到 2048 年。除了原始物質成分專利（病毒，心血管，神經系統和炎症性疾病）中涵蓋的適應症外，Hepion 還提出了各種使用方法專利申請，涵蓋了各種附加適應症（纖維化，癌症和血栓形成）。
Robert Foster, PharmD, PhD, Hepion's Chief Executive Officer, stated, "Rencofilstat is very challenging to formulate, owing to the physical-chemical properties of the molecule. Nevertheless, as awareness of its potential to address a number of significant unmet medical needs across a variety of indications continues to grow amongst researchers and drug developers in global markets, it is important this opportunity is well protected. To that end, our expanding intellectual property estate, including this new European patent, should ensure that rencofilstat has long-term market exclusivity."
Hepion 首席執行官 Pharmd 博士羅伯特·福斯特（Robert Foster）表示：「由於分子的物理化學性質，Rencofilstat 制定非常具有挑戰性。儘管如此，隨著其在全球市場的研究人員和藥物開發商之間解決許多重要未滿足的醫療需求的潛力持續增長，因此這個機會得到良好的保護非常重要。為此，我們不斷擴大的知識產權，包括這項新的歐洲專利，應確保 rencofilstat 具有長期的市場排他性。」
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧